Moreover, the combined inhibition of EHBP1L1 and immune checkpoint exhibits an enhanced antitumor effect in RCC preclinical patient‐derived xenograft (PDX) models compared to monotherapy. The gene discussed is EHBP1L1; the disease is renal cell carcinoma.